178 related articles for article (PubMed ID: 33051856)
1. Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis.
Bonafede M; Mehta R; Kim G; Sruti I; Tian M; Pelletier C; Goldfarb N
Pharmacoecon Open; 2021 Mar; 5(1):23-34. PubMed ID: 33051856
[TBL] [Abstract][Full Text] [Related]
2. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
3. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis.
Hersh CM; Brook RA; Beren IA; Rohrbacker NJ; Lebson L; Henke C; Phillips AL
J Med Econ; 2021; 24(1):479-486. PubMed ID: 33739915
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
[TBL] [Abstract][Full Text] [Related]
5. Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.
Merola D; Yong C; Noga SJ; Shermock KM
J Manag Care Spec Pharm; 2018 Oct; 24(10):1019-1026. PubMed ID: 30247101
[TBL] [Abstract][Full Text] [Related]
6. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
7. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
8. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis.
Burks J; Marshall TS; Ye X
Clinicoecon Outcomes Res; 2017; 9():251-260. PubMed ID: 28496344
[TBL] [Abstract][Full Text] [Related]
9. Absenteeism and health-benefit costs among employees with MS.
Brook RA; Rajagopalan K; Kleinman NL; Melkonian AK
Curr Med Res Opin; 2009 Jun; 25(6):1469-76. PubMed ID: 19422277
[TBL] [Abstract][Full Text] [Related]
10. Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients.
Freeman L; Kee A; Tian M; Mehta R
Clinicoecon Outcomes Res; 2021; 13():65-75. PubMed ID: 33519217
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
13. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
[TBL] [Abstract][Full Text] [Related]
14. Disease-Modifying Therapy Adherence and Associated Factors in a National Sample of Medicare Patients With Multiple Sclerosis.
Li P; Ladage VP; Berger J; Chahin S; Jhaveri M; Geremakis C; Doshi JA
Value Health; 2020 Mar; 23(3):328-334. PubMed ID: 32197728
[TBL] [Abstract][Full Text] [Related]
15. Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020.
Khakban A; Rodriguez Llorian E; Michaux KD; Patten SB; Traboulsee A; Oh J; Lynd LD;
Neurology; 2023 Feb; 100(9):e899-e910. PubMed ID: 36450607
[TBL] [Abstract][Full Text] [Related]
16. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
17. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.
Bonafede MM; Johnson BH; Watson C
Clinicoecon Outcomes Res; 2013; 6():11-20. PubMed ID: 24379685
[TBL] [Abstract][Full Text] [Related]
18. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.
Nicholas J; Boster A; Wu N; Yeh WS; Fay M; Kendter J; Huang MY; Lee A
Pharmacoecon Open; 2018 Mar; 2(1):31-41. PubMed ID: 29464673
[TBL] [Abstract][Full Text] [Related]
20. Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States.
Soliman AM; Surrey E; Bonafede M; Nelson JK; Castelli-Haley J
Adv Ther; 2018 Mar; 35(3):408-423. PubMed ID: 29450864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
